全文获取类型
收费全文 | 499153篇 |
免费 | 47162篇 |
国内免费 | 213篇 |
专业分类
546528篇 |
出版年
2018年 | 5634篇 |
2017年 | 5667篇 |
2016年 | 8655篇 |
2015年 | 13024篇 |
2014年 | 13925篇 |
2013年 | 17621篇 |
2012年 | 18512篇 |
2011年 | 16369篇 |
2010年 | 11746篇 |
2009年 | 10585篇 |
2008年 | 12932篇 |
2007年 | 13235篇 |
2006年 | 12479篇 |
2005年 | 18459篇 |
2004年 | 17421篇 |
2003年 | 15040篇 |
2002年 | 11632篇 |
2001年 | 19056篇 |
2000年 | 18320篇 |
1999年 | 15433篇 |
1998年 | 5417篇 |
1997年 | 5336篇 |
1996年 | 4940篇 |
1995年 | 4794篇 |
1994年 | 4719篇 |
1993年 | 4590篇 |
1992年 | 13299篇 |
1991年 | 12951篇 |
1990年 | 12812篇 |
1989年 | 12253篇 |
1988年 | 11606篇 |
1987年 | 11086篇 |
1986年 | 9986篇 |
1985年 | 10148篇 |
1984年 | 8202篇 |
1983年 | 7072篇 |
1982年 | 5409篇 |
1981年 | 4826篇 |
1980年 | 4519篇 |
1979年 | 8192篇 |
1978年 | 6154篇 |
1977年 | 5655篇 |
1976年 | 5325篇 |
1975年 | 6040篇 |
1974年 | 6549篇 |
1973年 | 6704篇 |
1972年 | 6154篇 |
1971年 | 5753篇 |
1970年 | 4936篇 |
1969年 | 4885篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
M Shadidy X Caubit R Olsen O M Seternes U Moens S Krauss 《Biochimica et biophysica acta》1999,1446(3):295-307
We have identified mouse and human FKBP60, a new member of the FKBP gene family. FKBP60 shares strongest homology with FKBP65 and SMAP. FKBP60 contains a hydrophobic signal peptide at the N-terminus, 4 peptidyl-prolyl cis/trans isomerase (PPIase) domains and an endoplasmic reticulum retention motif (HDEL) at the C-terminus. Immunodetection of HA-tagged FKBP60 in NIH-3T3 cells suggests that FKBP60 is segregated to the endoplasmic reticulum. Northern blot analysis shows that FKBP60 is predominantly expressed in heart, skeletal muscle, lung, liver and kidney. With N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide as a substrate, recombinant GST-FKBP60 is shown to accelerate effectively the isomerization of the peptidyl-prolyl bond. This isomerization activity is inhibited by FK506. mFKBP60 binds Ca2+ in vitro, presumably by its C-terminal EF-hand Ca2+ binding motif, and is phosphorylated in vivo. hFKBP60 has been mapped to 7p12 and/or 7p14 by fluorescence in situ hybridization (FISH). 相似文献
2.
3.
4.
5.
6.
Conventional therapies for prostate cancer, especially in its androgen-independent form, may result in the survival of small populations of resistant cells with tumor-initiating potential. These “cancer stem cells” are believed to be responsible for cancer relapse, and therapeutic strategies targeting these cells are of great importance. Telomerase is a ribonucleoprotein enzyme responsible for telomere elongation and is activated in the majority of malignancies, including prostate cancer, but is absent in most normal cells. Putative tumor-initiating cells have significant levels of telomerase, indicating that they are an excellent target for telomerase inhibition therapy. In this review, we present some evidence for the hypothesis that conventional therapies (standard chemotherapy and/or radiation therapy) in combination with telomerase inhibitors may result in effective and more durable responses. 相似文献
7.
8.
Based on its proven anabolic effects on bone in osteoporosis patients, recombinant parathyroid hormone (PTH1-34) has been evaluated as a potential therapy for skeletal repair. In animals, the effect of PTH1-34 has been investigated in various skeletal repair models such as fractures, allografting, spinal arthrodesis and distraction
osteogenesis. These studies have demonstrated that intermittent PTH1-34 treatment enhances and accelerates the skeletal repair process via a number of mechanisms, which include effects on mesenchymal
stem cells, angiogenesis, chondrogenesis, bone formation and resorption. Furthermore, PTH1-34 has been shown to enhance bone repair in challenged animal models of aging, inflammatory arthritis and glucocorticoid-induced
bone loss. This pre-clinical success has led to off-label clinical use and a number of case reports documenting PTH1-34 treatment of delayed-unions and non-unions have been published. Although a recently completed phase 2 clinical trial of PTH1-34 treatment of patients with radius fracture has failed to achieve its primary outcome, largely because of effective healing
in the placebo group, several secondary outcomes are statistically significant, highlighting important issues concerning the
appropriate patient population for PTH1-34 therapy in skeletal repair. Here, we review our current knowledge of the effects of PTH1-34 therapy for bone healing, enumerate several critical unresolved issues (e.g., appropriate dosing regimen and indications)
and discuss the long-term potential of this drug as an adjuvant for endogenous tissue engineering. 相似文献
9.
10.